Latest Ross Camidge Stories
University of Colorado Denver A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195). In 2011, the drug crizotinib earned accelerated approval by the US FDA to target the subset of advanced non-small cell lung cancers caused by rearrangements of the anaplastic lymphoma...
Study details side effect rate, mechanism and treatment A previous study by the University of Colorado Cancer Center reported the common side effect of low testosterone in men treated with the recently approved lung cancer agent, crizotinib. A new study published this week in the journal Cancer confirms this finding in a multi-national sample, details the mechanism of reduced testosterone, and provides promising preliminary evidence that widely available hormone replacement therapies can...
Health professionals led by a cancer specialist from the University of Edinburgh have put forward the case for finding new and fairer ways to assess the value of treatments for patients who will eventually die from their condition. Writing in the current edition of the British Medical Journal (10 June, 2005) the experts argue that this issue should be explored because of its impact on national decisions about which new treatments are funded. Lead author of the BMJ article, Dr Ross Camidge,...
- A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
- A gentle breeze; a waft; a breath.
- Any rumor that engages general attention.
- To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
- To breathe in or as in sleep.
- To utter in a whining or monotonous tone.